XML 17 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Income Statement - USD ($)
$ in Thousands
6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Profit or loss [abstract]    
Revenue $ 3,388 $ 3,422
Research & development (12,647) (13,430)
Manufacturing commercialization (6,746) (12,760)
Management and administration (11,482) (13,281)
Fair value remeasurement of contingent consideration (337) 5,989
Fair value remeasurement of warrant liability 4,434 (712)
Other operating income and expenses 1,068 (39)
Finance costs (10,319) (10,685)
Loss before income tax (32,641) (41,496)
Income tax benefit/(expense) 102 126
Loss attributable to the owners of Mesoblast Limited $ (32,539) $ (41,370)
Earnings per share [abstract]    
Basic - losses per share (in dollars per share) $ (0.0382) $ (0.0564)
Diluted - losses per share (in dollars per share) $ (0.0382) $ (0.0564)